Evidence map›Paper›PMID 30456446›Full record

ArticleDermatology and therapy2019

Burden of Herpes Zoster in the Japanese Population with Immunocompromised/Chronic Disease Conditions: Results from a Cohort Study Claims Database from 2005-2014.

Shinichi Imafuku, Taizo Matsuki, Akiko Mizukami, Yasushi Goto, Sabrina de Souza, Céline Jégou, Veronique Bianco, Dominique Rosillon, Chie Ito, Desmond Curran and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 9 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 9 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Global herpes zoster burden in adults with COPD: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Immune Dysregulation in Acute Herpes Zoster: Predictive Factors for Postherpetic Neuralgia.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Shinichi ImafukuDepartment of Dermatology, School of Medicine, Fukuoka University, Fukuoka, Japan.
Taizo MatsukiHealthoutcomes Department, GSK, Tokyo, Japan. taizo.2.matsuki@gsk.com.ORCID http://orcid.org/0000-0002-0591-4261
Akiko MizukamiHealthoutcomes Department, GSK, Tokyo, Japan.
Yasushi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Sabrina de SouzaKeyrus Biopharma C/O GSK, London, UK.
Céline JégouBusiness and Decision Life Sciences C/O GSK, Wavre, Belgium.
Veronique BiancoBiostatistics and Statistical Programming, GSK, Rockville, USA.
Dominique RosillonBiostatistics and Statistical Programming, GSK, Wavre, Belgium.
Chie ItoJMDC Co Ltd., Tokyo, Japan.
Desmond CurranVaccines Health Outcomes Department, GSK, Wavre, Belgium.
Katsiaryna HollHealthoutcomes Department, GSK, Tokyo, Japan.
Fukuoka University · JPGlaxoSmithKline (Belgium) · BEHealth Outcomes Solutions (United States) · USKarus Therapeutics (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of this study is to describe the disease burden and costs of herpes zoster (HZ) in the general adult Japanese population or patients with immunocompromised (IC) conditions or chronic disorders.

methodsA retrospective cohort study of individuals aged 18-74 years was conducted using January 2005 to December 2014 records from the Japan Medical Data Center claims database. Twenty-eight IC conditions and chronic disorders were defined by diagnosis codes and/or procedures/treatments. HZ and its related complications were identified. Incidence rates (IR), frequency of HZ-related complications, healthcare resource utilization (HRU), and direct medical costs were estimated. HRU and costs were estimated on a subcohort of HZ cases occurring April 2012-January 2014.

resultsThe overall IR of HZ in the total cohort of 2,778,476 adults was 4.92/1000 person-years (PY) [95% confidence interval (CI): 4.86-4.98] and increased with age. The IR in the IC cohort (51,818 subjects) was 8.87/1000 PY (95% CI: 8.29-9.48), ranging from 5.55/1000 PY (95% CI: 4.26-7.09) in psoriasis to 151.68/1000 PY (95% CI: 111.45-201.71) in hematopoietic stem cell transplant recipients; most IRs were in the range 6-10/1000 PY. The IRs in individuals with chronic disorders were also relatively high, in the range 5.40-12.90/1000 PY. The frequency of postherpetic neuralgia was 4.01% (95% CI: 3.72-4.33) in the total cohort and 11.73% (95% CI: 9.01-14.93) in the IC cohort. The mean [standard deviation (SD)] number of outpatient visits was 3.4 (4.9) and 5.0 (5.7), respectively, and the proportion of HZ patients hospitalized was 2.20% and 6.70%, respectively. The mean (SD) direct medical cost per HZ episode was ¥34,664 (¥54,433) and ¥55,201 (¥92,642) in the total and IC cohort, respectively.

conclusionsThe elevated burden of HZ in Japanese individuals harboring IC conditions and chronic disorders documented in our study underlines the need for prevention of HZ in people with these conditions.

fundingGlaxoSmithKline Biologicals SA.

Indexed as

Claims databaseHealthcare resource utilizationHerpes zosterImmunocompromisedJapanMedical costPostherpetic neuralgia

Identifiers

PMID30456446
PMCPMC6380970
OpenAlexW2900480779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.